
Ovarian Cancer: The "e;Gynaecological Challenge"e; from Diagnostic Work-Up to Cytoreduction and Chemotherapy. Volume 1
Beschreibung
Weitere Details
Weitere Ausgaben
Inhalt
- Intro
- Contents
- Preface
- Chapter 1
- Ovarian Cancer Pathology and Surgery, Historical Pearls from the Pioneering Greeks and the General Term Gynecologic Cancer to Modern Histopathology and Ovarian Malignancy
- Introduction
- Conclusion
- References
- Chapter 2
- Ovarian Cancer Screening
- Introduction
- Screening for Ovarian Cancer in the General Population
- What Have We Learnt Over the Past Two Decades
- Screening for Ovarian Cancer in Women at High Risk
- Can Genetics or Epidemiological Data Improve Screening Efforts?
- Current Dilemmas and Controversies
- The Future
- Conclusion
- References
- Chapter 3
- The Role of Ultrasounds in the Diagnosis and Management of Adnexal Tumors
- Introduction
- Evaluation of Adnexal Tumors
- Personal History
- Family History
- Physical Examination
- Ultrasound Examination
- Cyst/Tumor Descriptions
- Solid/Cystic and Contents
- Papillary Projections
- Vascularity
- Acoustic Shadowing
- Acoustic Streaming
- Ascites
- Peritoneal Disease
- Mobility
- Classification of Common Adnexal Tumors Using Pattern Recognition
- Functional Cysts: Simple, Heamorrhagic and Corpora Lutea
- Clinical Presentation
- Ultrasonographic Findings
- Endometrioma
- Clinical Presentation
- Ultrasonographic Findings
- Germ Cell Tumors: Mature Cystic Teratoma (Dermoid Cyst)
- Clinical Presentation
- Ultrasonographic Findings
- Germ Cell Tumors: Stuma Ovarii
- Clinical Presentation
- Ultrasonographic Findings
- Sex-Chord Stromal Tumors: Fibroma/Fibrothecoma
- Clinical Presentation
- Ultrasonographic Findings
- Sex-Chord Stromal Tumors: Granulosa Cell Tumors (GCT)/ Sertoli-Cell/Leydig-Cell
- Clinical Presentation
- Ultrasonographic Findings
- Epithelial Tumors: Benign Cystadenoma/Cystadenofibroma
- Clinical Presentation
- Ultrasonographic Findings
- Epithelial Tumors: Brenner Tumors
- Clinical Presentation
- Ultrasonographic Findings
- Epithelial Tumors: Borderline Ovarian Tumors (BOT)
- Clinical Presentation
- Ultrasonographic Findings
- Epithelial Tumors: Epithelial Adenocarcinoma
- Clinical Presentation
- Ultrasonographic Findings
- Non-epithelial Malignant Tumors: Dysgerminomas, Immature Teratomas
- Clinical Presentation
- Ultrasonographic Findings
- Metastatic
- Clinical Presentation
- Ultrasonographic Findings
- Non-ovarian: Tubal Structure
- Clinical Presentation
- Ultrasonographic Findings
- Non-ovarian: Tubal Cancer
- Clinical Presentation
- Ultrasonographic Findings
- Non-ovarian: Peritoneal Pseudocyst
- Clinical Presentation
- Ultrasonographic Findings
- Alternative Diagnostic Tools
- RMI
- International Ovarian Tumor Analysis (IOTA) Logistic Regression Models LR1 and LR2
- IOTA Simple Rules
- ADNEX Model
- O-RADS
- Conclusion
- References
- Chapter 4
- Preoperative Biomarkers to Predict Resectability of Patients with Ovarian Cancer
- Introduction
- Ovarian Cancer
- Epidemiology
- Histology
- Prognosis
- Resectability
- Cytoreductive Surgery
- Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery
- Complete Resection of All Visible Disease Is the Goal of Surgical Treatment
- Preoperative Assessment of Resectability
- Preoperative Imaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)/CT
- Laparoscopic Assessment
- Rationale
- First Attempts
- A Laparoscopic Score to Predict Optimal Primary Cytoreduction
- Validation of the Laparoscopic Score
- Biomarkers
- CA-125
- HE4
- HE4 in Combination with CA-125 to Identify the Presence of Ovarian Cancer
- Preoperative Biomarkers to Predict Resectability
- CA-125 and Primary Debulking Surgery
- CA-125 and Interval Debulking Surgery
- CA-125 and Secondary Cytoreduction for Recurrent Ovarian Cancer
- HE4 and Primary Debulking Surgery
- HE4 and Interval Debulking Surgery
- HE4 and Secondary Cytoreduction for Recurrent Ovarian Cancer
- The Value of CA125 and HE4 to Predict the Resectability of Ovarian Cancer According to the Latest Guidelines
- Conclusion
- References
- Chapter 5
- Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) Findings in Ovarian Cancer
- Introduction
- Conclusion
- References
- Chapter 6
- The Role of 18FDG PET/CT Scans in Ovarian Cancer Patients
- Introduction
- 18 FDG PET/CT Scan
- Estimation of Lesion 18F-FDG Uptake
- Initial Diagnosis and Staging in Patients Presenting with a Pelvic Mass Suspicious for Ovarian Cancer
- Prognostic Value/Disease Prognostication
- Therapy Assessment
- Relapse Detection
- Impact of PET/CT on the Treatment Planning
- Conclusion
- References
- Chapter 7
- The Pathogenesis of Ovarian Cancer
- Introduction
- Risk Factors
- Investigation on the Cell of Origin
- Ovarian Carcinogenesis: Type 1 and Type 2
- Type 1
- Endometrial Carcinoma (EC) and Clear Cell Carcinoma (CCC)
- Mucinous Carcinoma (MC)
- Low-grade Serous Carcinoma (LGSC)
- Type 2
- High-grade Serous Carcinoma (HGSCs)
- Conclusion
- References
- Chapter 8
- Inherited Ovarian Cancer-Linked Syndromes and Management
- Introduction
- Identifying Women at Risk of Inherited Ovarian Cancer
- How to Determine Level of Risk
- BRCA1 and BRCA2
- Lynch Syndrome
- 'Moderate Risk' Ovarian Cancer Susceptibility Genes - BRIP1, PALB2, RAD51C, RAD51D
- Low Penetrance Ovarian Cancer Susceptibility Alleles
- Surveillance
- Risk-Reducing Surgery
- Surgical-Pathological Considerations
- Histological Sampling to Reduce Risk of Missing STIC/Cancer
- Future Management Possibilities
- Conclusion
- Acknowledgments
- References
- Ovarian Cancer Statistics | Cancer Research UK
- Welcome to CanRisk
- Chapter 9
- Pathology of Epithelial Ovarian Tumors
- Abstract
- Ovarian Carcinoma
- Ovarian Tumourigenesis: A Proposed Model Based on Morphological and Molecular Genetic Analysis
- Type I Ovarian Carcinomas
- Type II Ovarian Carcinomas
- To Discuss
- General Introduction
- 5th Who Classification (2020) of Ovarian Epithelial Tumours
- Epithelial Tumors
- Differences from Previous Studies
- Typing of Ovarian Carcinomas
- Other Reasons for Typing
- Recent Population-Based (Washington/British Columbia)
- Low Stage (I/II) Versus High Stage (III/IV)
- Grading of Ovarian Carcinoma
- Serous Tumours
- Serous Cystadenoma, Adenofibroma and Surface Papilloma of the Ovary
- Serous Borderline Tumour of the Ovary
- Ovarian Serous Carcinoma (OSC)
- Ovarian Serous Carcinoma (OSC)-Recent Developments
- Pathogenesis (Low Grade Serous)
- Pathogenesis (High Grade Serous)
- Morphology
- Corellation between Grading Systems
- Low Grade Serous Carcinoma of the Ovary
- High Grade Serous Carcinoma
- Molecular (Low Grade Serous)
- Molecular (High Grade Serous)
- Behaviour and Prognosis (Low Grade Serous)
- Behaviour and Prognosis (High Grade Serous)
- Primary Peritoneal Serous Carcinoma (PPSC)
- Gog Criteria for PPSC
- Ovarian Mucinous Tumours
- Mucinous Cystadenoma and Adenofibroma
- Mucinous Borderline Tumour
- Mucinous Carcinoma of the Ovary
- Mucinous Carcinoma - Primary or Secondary?
- Features Favouring Metastasis with Mucinous Ovarian Carcinoma
- Endometrioid Cystadenoma and Adenofibroma
- Endometrioid Borderline Tumour
- Endometrioid Carcinoma of the Ovary
- Clear Cell Adenoma and Cystadenofibroma
- Clear Cell Borderline Tumour
- Clear Cell Carcinoma of the Ovary
- Seromucinous Cystadenoma and Adenofibroma
- Seromucinous Borderline Tumour
- Seromucinous Carcinoma
- Brenner Tumour
- Borderline Brenner Tumour
- Malignant Brenner Tumour
- Mesonephric-Like Adenocarcinoma
- Undifferentiated and Dedifferentiated Carcinomas of the Ovary
- Carcinosarcoma of the Ovary
- Mixed Carcinoma of the Ovary
- References
- Chapter 10
- Pathology of Non-epithelial Ovarian Tumors
- Introduction
- Germ Cell Tumors
- Ovarian Teratomas
- Pathogenesis of Teratomas
- Clinical Findings
- Imaging Studies
- Management
- Pathology
- Prognosis
- Monodermal Teratomas
- Pathogenesis
- Clinical Findings
- Imaging
- Differential Diagnosis
- Management
- Pathology
- Prognosis
- Ovarian Dysgerminoma
- Pathogenesis
- Clinical Presentation
- Management
- Pathology
- Differential Diagnosis
- Prognosis
- Yolk Sac Tumor (Endodermal Sinus Tumor, Teilum Tumor)
- Pathogenesis
- Clinical Findings
- Imaging Studies
- Differential Diagnosis
- Management
- Pathology
- Prognosis
- Non-gestational Choriocarcinoma
- Pathogenesis
- Clinical Findings
- Imaging
- Differential Diagnosis
- Management
- Pathology
- Prognosis
- Mixed Germ Cell -Sex Cord -Stromal Tumors
- Gonadoblastoma
- Pathogenesis
- Clinical Findings
- Imaging
- Differential Diagnosis
- Management
- Pathology
- Prognosis
- Sex Cord-Stromal Tumors
- Granulosa Cell Tumors of the Ovary
- Incidence
- Pathogenesis
- Diagnosis
- Treatment
- Pathology
- Prognosis
- Ovarian Thecoma
- Pathogenesis
- Clinical Findings
- Management
- Pathology
- Prognosis
- Ovarian Fibroma
- Pathogenesis
- Clinical Findings
- Imaging
- Differential Diagnosis
- Management
- Pathology
- Prognosis
- Sertoli-Stromal Cell Tumors (Androblastomas)
- Sertoli-Leydig Cell Tumors
- Pathogenesis
- Clinical Findings
- Imaging
- Differential Diagnosis
- Management
- Pathology
- Prognosis
- Conclusion
- References
- Chapter 11
- The Role of Immunohistochemistry in Ovarian Tumors
- Introduction
- Immunohistochemical Biomarkers
- Cytokeratin 7 (CK7)
- Cytokeratin 20 (CK20)
- Carbohydrate Antigen 125 (CA 125)
- PAX8
- Wilms Tumor 1 (WT1)
- Other Immunohistochemical Markers
- Immunophenotypic Features of Epithelial Ovarian Tumors
- Ovarian Serous Carcinomas (OSCs)
- Ovarian Mucinous Carcinomas (OMCs)
- Ovarian Endometrioid Carcinomas (OECs)
- Ovarian Clear Cell Carcinomas (OCCCs)
- Brenner Tumors - Ovarian Transitional Cell Tumors
- Other Ovarian Epithelial Tumors
- Immunophenotypic Features of Ovarian Sex Cord-Stromal Tumors (OSCSTs)
- Fibroma - Thecoma and Related Tumors
- Granulosa Cell Tumors
- Sertoli-Leydig Cell Tumors
- Sertoli Cell Tumors
- Leydig Cell Tumors
- Immunophenotypic Features of Ovarian Malignant Germ Cell Tumors (OMGCTs)
- Dysgerminoma
- Yolk Sac Tumor
- Embryonal Carcinoma
- Choriocarcinoma
- Immature Teratomas
- Conclusion
- References
- Chapter 12
- Molecular Pathology of Epithelial Ovarian Tumors
- Introduction
- Pathogenetic Mechanisms of Epithelial Ovarian Tumors
- Molecular Features of Epithelial Ovarian Tumors
- High-grade Serous Ovarian Carcinomas (HGSCs)
- Low-grade Serous Ovarian Carcinomas (LGSCs)
- Endometrioid Ovarian Carcinomas (EOCs)
- Mucinous Ovarian Carcinomas (MOCs)
- Clear Cell Ovarian Carcinomas (CCOCs)
- Small Cell Ovarian Carcinomas (SCOCs)
- Brenner Ovarian Tumors
- Mesonephric-like Ovarian Carcinomas (MLOCs)
- Dedifferentiated and Undifferentiated Ovarian Carcinomas and Carcinosarcomas
- References
- Chapter 13
- An Approach to Borderline Ovarian Tumors
- Introduction
- Epidemiology
- Biopathology
- Peritoneal Implants
- Micropapillary Pattern of Serous BOT
- Microinvasion in Serous BOT
- Diagnosis
- Staging and Risk Assessment
- Primary Treatment of Early Stage
- Fertility Sparing Surgery: Clinical Evaluation and Obstetrical Outcomes
- Primary Treatment of Advanced Stage
- Treatment of Recurrent Disease
- Conclusion
- References
- Chapter 14
- Prophylactic Salpingo-Oophorectomy in High-Risk Patients
- Introduction
- STICs and p53 Signatures
- Breast Cancer (BC) and Ovarian Cancer (OC) Risk
- Peritoneal Cancer Risk
- Uterine Cancer Risk
- Conclusion
- References
- Chapter 15
- The Management of Early-Stage Epithelial Ovarian Cancer
- Introduction
- Management of Early Ovarian Cancer
- Surgical Staging
- Chemotherapy
- Conclusion
- References
- Chapter 16
- Fertility Sparing in Ovarian Cancer Patients
- Introduction
- Indications of Fertility Sparing in Ovarian Cancer
- Fertility Sparing Procedures in Ovarian Cancer
- Oncological Outcomes after Fertility Sparing Treatment in Ovarian Cancer
- Reproductive and Obstetrics Outcomes after Fertility Sparing Treatment in Ovarian Cancer
- Follow-up of Patients
- Conclusion
- References
- Chapter 17
- The Local-Regional Control of Ovarian Cancer
- Introduction
- Tumor Cell Entrapment (TCE)
- Tumor Cell Entrapment Observed with Reoperative Surgery for Ovarian Cancer
- Documentation of Tumor Cell Entrapment after Hysterectomy at the Time of Cytoreductive Surgery
- Current Recommendations for Surgery in Primary Epithelial Ovarian Cancer
- Rule of Least Margins and Volumes
- Perioperative Intraperitoneal Chemotherapy to Reduce Tumor Cell Entrapment
- Perioperative Intraperitoneal Lavage Methodologies May Reduce Tumor Cell Entrapment
- Tumor Cell Entrapment Following Hysterectomy, What Does It Cost?
- Data from Prior Surgical Score (PSS) Supports the Importance of Tumor Cell Entrapment (TCE)
- Comparisons of Initial versus Reoperative Surgery for Epithelial Ovarian Cancer
- Conclusion
- References
- Chapter 18
- Surgical Management of Advanced Epithelial Ovarian Cancer
- Introduction
- The Evolution of Debulking Surgery in Advanced Stage Ovarian Cancer
- Cytoreductive Surgery in Advanced Stage Ovarian Cancer
- Upper Abdominal Surgery
- Conclusion
- References
- Chapter 19
- Primary Versus Interval Debulking Surgery in Ovarian Cancer Patients
- Introduction
- Randomized Controlled Trials
- EORTC 55971 Trial
- CHORUS Trial
- JCOG0602 Trial
- SCORPION Trial
- Limitations and Criticisms of RCTs
- Ongoing RCTs
- Trial of Radical Upfront Surgical Therapy in Advanced Ovarian Cancer (TRUST)
- Study of Upfront Surgery versus Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer (SUNNY)
- Systematic Reviews of Only RCTs
- Systematic Reviews of 'RCTs and Non-randomized Studies'
- Large Retrospective Study
- Recent Cochrane Review
- Special Issues
- The Number of Cycles in NACT
- Timing of IDS
- Patient Selection, Burden of Disease and Factors Determining Optimality
- Age and Performance Status
- Tumor Size
- Platinum Refractory Disease
- Other Histological Types
- Residual Tumor
- Experience and Skills of the Surgeon
- Upper Abdominal Surgery
- FIGO Stage
- Scoring Systems
- Surgical Concerns about NACT
- Selection Criteria
- Intraperitoneal Chemotherapy and HIPEC
- Quality of Life
- Cancer Genetics, Immunotherapy, Bevacizumab and New Agents
- Cost Effectiveness
- Conclusion
- References
- Chapter 20
- Lymphadenectomy in Ovarian Cancer Surgery
- Introduction
- Lymphadenectomy in Early-Stage Ovarian Cancer
- The Rate of Lymphatic Metastasis
- Prognostic and Therapeutic Effects of Lymphadenectomy
- Lymphadenectomy in Advanced Staged Ovarian Cancer
- The Rate of Lymphatic Metastasis
- The Role of Prognostic and Therapeutic Effect in Primary Cytoreduction
- References
- Chapter 21
- Serous Papillary Primary Peritoneal Carcinoma
- Introduction
- Clinical Features
- Diagnosis
- Investigation
- Invasive Procedures for Diagnosis
- Treatments
- Traditional Treatment
- Innovative Treatment
- Results with CRS HIPEC
- Conclusion
- References
- Chapter 22
- Ovarian Carcinosarcoma
- Introduction
- Highlights
- References
- Chapter 23
- Krukenberg Tumors
- Introduction
- Epidemiology
- Pathogenesis
- Metastatic Organotropism
- Clinical Signs
- Diagnosis
- Imaging Methods
- The Role of CA 125
- Endoscopic Methods
- Histopathological Diagnosis
- Macroscopic Description
- Histology
- The Role of Immunohistochemistry
- Staging
- Management
- The Role of CRS for STOs
- Adjuvant Chemotherapy Following CRS
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Prognosis
- Conclusion
- References
- Chapter 24
- Pseudomyxoma Peritonei
- Introduction
- Consensus on Preoperative Evaluation
- Intraoperative Evaluation
- Operating Procedures of CRS + HIPEC
- Perioperative Management
- Controversies on HIPEC Regimens
- The Role of Systemic Chemotherapy
- Controversies on HIPEC Methods
- Controversies on EPIC
- Conclusion
- References
- Chapter 25
- Ovarian Malignancies during Pregnancy
- Introduction
- Epidemiology
- Patient Presentation
- Types of Adnexal Masses in Pregnancy: Sonographic Evaluation
- Cysts
- Pregnancy Associated Masses
- Masses
- Complex Masses
- Malignant Neoplasms
- Anatomopathological Diagnosis
- Patient Evaluation for Treatment
- Patient Selection for Surgery
- Timing
- Preoperative Assessment
- Secondary Imaging
- Tumor Markers in Ovarian Malignancy
- Surgery
- Chemotherapy
- Prognosis: Obstetrical Outcomes after Ovarian Cancer in Pregnancy
- Conclusion
- References
- Index
- Editors' Contact Information
- Blank Page
Systemvoraussetzungen
Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)
Systemvoraussetzungen:
- Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).
- Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions oder die App PocketBook (siehe E-Book Hilfe).
- E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)
Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist.
Mit Adobe-DRM wird hier ein „harter” Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.
Bitte beachten Sie: Wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!
Weitere Informationen finden Sie in unserer E-Book Hilfe.